Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
4(100.0%)
4Total
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01970410Phase 4Completed

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Role: collaborator

NCT04964700Unknown

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Role: lead

NCT03092544Phase 4Unknown

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

Role: lead

NCT02683863Phase 4Completed

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Role: lead

NCT01968902Phase 4Completed

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

Role: lead

All 5 trials loaded